Retraction Note to: The BRCA2 variant c.68–7 T > A is associated with breast cancer
© The Author(s). 2018
Received: 16 April 2018
Accepted: 16 April 2018
Published: 2 May 2018
The original article was published in Hereditary Cancer in Clinical Practice 2017 15:20
This article  has been retracted at the request of the authors. Upon re-review of the data, the authors identified coding errors in this study. Due to an error in the SQL query, the conclusions drawn in the article are incorrect. A re-examination of the data shows that there is no association between familial breast cancer and the BRCA2 variant c.68–7 T > A. Another recent study suggests that the variant is not pathogenic . All authors agree to this retraction.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Møller P, et al. The BRCA2 variant c.68-7 T>a is associated with breast cancer. Hered Cancer Clin Pract. 2017;15:20.View ArticlePubMedPubMed CentralGoogle Scholar
- Colombo M, et al. The BRCA2 c.68-7T > a variant is not pathogenic: a model for clinical calibration of spliceogenicity. Hum Mutat. 2018;39:729–41.View ArticlePubMedGoogle Scholar